跳至主要内容
临床试验/ACTRN12617000552381
ACTRN12617000552381终止未知

Impact of Exercise Intervention on the Phenome (Metabolism and Predictive Complications) in Well Characterised Pre-diabetes and New Onset Type 2 diabetes Cohorts in China and Australia.

The University of Sydney0 个研究点目标入组 162 人开始时间: 2017年4月20日最近更新:
适应症

试验速览

阶段
未知
状态
终止
入组人数
162

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Open (masking not used)

入排标准

年龄范围
18 Years 至 o limit(—)
性别
All

入选标准

  • BMI greater than or equal to 25 kg/m2 (Non-Asian participants) or BMI greater than or equal to 23 kg/m2 (Asian participants)
  • - Willing to undertake, and have no contraindications to, exercise testing and a program involving high intensity interval training program, resistance training or stretching
  • - Willing to give written informed consent
  • - Adequate understanding of national language
  • - Access to either phone or internet (this is necessary when being contacted by the instructors throughout the duration of the trial)
  • - Maximum weight of 140kg (equivalent MRI habitus limit)
  • - No change in medication or dose for the previous three months
  • - 90 participants at each site will be recruited from each of three glucose groups as defined by any one of the ADA criteria. That is Type 2 Diabetes Mellitus - HbA1c greater than or equal to 6.5%, Fasting Plasma Glucose (FPG) greater than or equal to 7.0 mmol/L, 2h post-Oral Glucose Tolerance Test Plasma Glucose (2hOGTT) greater than or equal to 11.1 mmol/L; Pre-diabetes - one occasion of any of the following in a participants medical history: HBA1c greater than or equal to 5.7% but less than 6.5%, FPG greater than or equal to 5.6 mmol/L but less than 7.0 mmol/L, 2hOGTT greater than or equal to 7.8 mmol/L but less than 11.1 mmol/L; Normal Glucose Profile - HbA1c less than 5.7%; FPG less than 5.6%; 2hOGTT less than 5.6 mmol/L.

排除标准

  • - Untreated dense insensate peripheral neuropathy that contraindicates exercise testing and training (as assessed by medical assessment)
  • - Significant cardiovascular disease including current angina; myocardial infarction or stroke within the past 6 months; heart failure; symptomatic peripheral vascular disease
  • - Active foot ulcer
  • - Musculoskeletal condition affecting ability to undertake exercise testing and training
  • - Self-reported average weekly intake of alcohol >140g per week
  • - Abnormalities noted by medical officer based on the resting ECG suggestive of unrecognised myocardial ischaemia: q waves, or ST wave depression.
  • - Self-reported currently completing >75 min/week high intensity exercise or >150 min/week moderate intensity exercise.
  • - Pregnancy, lactation or plans to become pregnant in the next 2 years.
  • - Claustrophobia or ferrous metal implants/devices which contraindicate MRI scan.
  • - Thiazolidinedione medication
  • - History of Hepatitis B or C which has not been cured
  • - Advanced chronic renal impairment (CKD state 4 or 5 or EFGR< 30)
  • - Cirrhosis
  • - Malignancy which is currently active or in remission for less than five years after last treatment (local basal and squamous cell skin cancer allowed)
  • - Blood donation or transfusion within the past month
  • - Haemoglobin concentration below local laboratory reference values (i.e. anaemia).
  • - Alanine Transaminase (ALT) and/or Apartate Transaminase (AST) >3 times the Upper Limit of Normal (local laboratory reference values)
  • - Any other condition deemed by the study physician that would prevent participation in the trial.
  • - Weight change of greater than or equal to 5% in the past three months.

研究者

相似试验